ArticleParasites & vectors2025
Evaluation of the effectiveness of Aquatain, Bacillus thuringiensis var. israelensis, and Temephos on Anopheles arabiensis and Anopheles stephensi larvae in the laboratory and field settings.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Ovicidal and larvicidal activity of the Impatiens rothii and Salvia officinalis extracts against Anopheles stephensi (Culicidae: Diptera) in laboratory conditions.Malaria journal · 2026Article
- NativeJournal of tropical medicine · 2026Article
- Susceptibility ofCurrent research in parasitology & vector-borne diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main tools to control malaria vectors in sub-Saharan Africa are long-lasting insecticidal nets and indoor residual spraying. However, their sustainability is threatened by the emergence of insecticide resistances, behavioral avoidance and presence of outdoor biting mosquito populations. Thus, complementary interventions such as larval source management, which includes larviciding, are required to achieve better results in malaria vector control. This study aimed to evaluate the effectiveness of three larvicides (Aquatain AMF
methodsThe tests on insectary colony and field-collected immature stages of the mosquitoes were conducted in the laboratory. For this, the third and fourth larval instars of An. arabiensis and An. stephensi were placed in trays measuring 50 cm × 40 cm, and larvicides were applied to the treatments while the control trays were left untreated. In addition, the larvicides were applied to selected natural habitats, and their effects on the reduction of the immature stages' density were estimated.
resultsIn the laboratory, susceptible An. arabiensis showed mortality rates of 95% with Aquatain, 100% with Bti and 100% with Temephos, while An. stephensi showed 60% with Aquatain, 84% with Bti and 100% with Temephos. The percentage of larval mortalities among wild An. arabiensis collected from the field and exposed to Aquatain, Bti and Temephos were 97%, 100% and 100%, respectively, whereas those of An. stephensi were 74%, 99% and 100%, respectively. During the natural field study, the reductions in immature stages were as follows: 77%, 96% and 95% in Adama; 89%, 95% and 94% in Metahara; and 92%, 84% and 96% in Awash for Aquatain, Bti and Temephos, respectively.
conclusionsThe three larvicides, Aquatain, Temephos and Bti, provided high levels of larviciding efficacies in both laboratory and field evaluations. Despite its effectiveness, Temephos caused the water to turn whitish and emitted a strong odor that made the community wary regarding the treated habitats. Therefore, we recommend using Aquatain in mosquito control programs as a complementary malaria vector control tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.